Endotypes of primary osteoarthritis identified by plasma metabolomics analysis.
Aged
Arginine
/ blood
Body Mass Index
Carnitine
/ analogs & derivatives
Case-Control Studies
Coronary Disease
/ epidemiology
Diabetes Mellitus
/ epidemiology
Factor Analysis, Statistical
Fasting
/ blood
Female
Humans
Logistic Models
Lysophosphatidylcholines
/ blood
Male
Metabolomics
Muscle Weakness
/ blood
Osteoarthritis, Hip
/ blood
Osteoarthritis, Knee
/ blood
Osteoporosis
/ epidemiology
Palmitic Acid
/ blood
Prevalence
Quality Control
Wasting Syndrome
/ blood
arginine
butyrylcarnitine
endotypes
lysophosphatidylcholine
osteoarthritis
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
18 06 2021
18 06 2021
Historique:
received:
27
06
2020
revised:
14
09
2020
pubmed:
8
11
2020
medline:
20
8
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
To identify endotypes of osteoarthritis (OA) by a metabolomics analysis. Study participants included hip/knee OA patients and controls. Fasting plasma samples were metabolomically profiled. Common factor analysis and K-means clustering were applied to the metabolomics data to identify the endotypes of OA patients. Logistic regression was utilized to identify the most significant metabolites contributing to the endotypes. Clinical and epidemiological factors were examined in relation to the identified OA endotypes. Six hundred and fifteen primary OA patients and 237 controls were included. Among the 186 metabolites measured, 162 passed the quality control analysis. The 615 OA patients were classified in three clusters (A, 66; B, 200; and C, 349). Patients in cluster A had a significantly higher concentration of butyrylcarnitine (C4) than other clusters and controls (all P < 0.0002). Elevated C4 is thought to be related to muscle weakness and wasting. Patients in cluster B had a significantly lower arginine concentration than other clusters and controls (all P < 7.98 × 10-11). Cluster C patients had a significantly lower concentration of lysophosphatidylcholine (with palmitic acid), which is a pro-inflammatory bioactive compound, than other clusters and controls (P < 3.79 × 10-6). Further, cluster A had a higher BMI and prevalence of diabetes than other clusters (all P ≤ 0.0009), and also a higher prevalence of coronary heart disease than cluster C (P = 0.04). Cluster B had a higher prevalence of coronary heart disease than cluster C (P = 0.003) whereas cluster C had a higher prevalence of osteoporosis (P = 0.009). Our data suggest three possible clinically actionable endotypes in primary OA: muscle weakness, arginine deficit and low inflammatory OA.
Identifiants
pubmed: 33159799
pii: 5960205
doi: 10.1093/rheumatology/keaa693
pmc: PMC8213424
doi:
Substances chimiques
Lysophosphatidylcholines
0
butyrylcarnitine
25576-40-3
Palmitic Acid
2V16EO95H1
Arginine
94ZLA3W45F
Carnitine
S7UI8SM58A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2735-2744Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
J Rheumatol. 2015 May;42(5):859-65
pubmed: 25729031
J Anat. 2010 Mar;216(3):279-91
pubmed: 20070426
Rheumatology (Oxford). 2016 Sep;55(9):1566-74
pubmed: 27160277
Mol Genet Metab. 2003 Apr;78(4):239-46
pubmed: 12706374
Semin Arthritis Rheum. 2009 Oct;39(2):71-80
pubmed: 19589561
Hum Genet. 2008 Aug;124(1):43-56
pubmed: 18523805
Scand J Rheumatol. 2011;40(4):308-16
pubmed: 21417548
Rheumatology (Oxford). 2009 Mar;48(3):277-80
pubmed: 19153142
Lancet. 2011 Jun 18;377(9783):2115-26
pubmed: 21684382
J Nutr. 2004 Oct;134(10 Suppl):2880S-2887S; discussion 2895S
pubmed: 15465805
Curr Rheumatol Rep. 2013 May;15(5):328
pubmed: 23508809
BMJ Open. 2014 Nov 19;4(11):e006286
pubmed: 25410606
Osteoarthritis Cartilage. 2016 May;24(5):827-34
pubmed: 26708258
J Vet Med Sci. 2013 May 2;75(4):497-502
pubmed: 22971527
Clin Immunol. 2002 Dec;105(3):315-25
pubmed: 12498813
Osteoarthritis Cartilage. 2009 Aug;17(8):1040-8
pubmed: 19289234
Semin Arthritis Rheum. 2014 Dec;44(3):271-82
pubmed: 25086470
Cell Metab. 2007 Nov;6(5):348-51
pubmed: 17983580
Vasc Med. 2002 Aug;7(3):203-11
pubmed: 12553744
ISRN Pharmacol. 2011;2011:851870
pubmed: 22084721
Prostaglandins Other Lipid Mediat. 2001 Apr;64(1-4):11-20
pubmed: 11324701
Curr Opin Rheumatol. 1997 May;9(3):259-62
pubmed: 9204263
Sci Rep. 2017 Dec 13;7(1):17528
pubmed: 29235526
Med Sci Monit. 2013 Nov 26;19:1057-62
pubmed: 24276564
Sci Rep. 2019 Jul 4;9(1):9648
pubmed: 31273319
Arthritis Res Ther. 2019 Nov 6;21(1):224
pubmed: 31694709
Ann Rheum Dis. 2010 Jun;69(6):1227-31
pubmed: 20388742
Bioorg Chem. 2002 Apr;30(2):119-32
pubmed: 12020136
Arthritis Rheum. 1991 May;34(5):505-14
pubmed: 2025304
Atherosclerosis. 2000 Aug;151(2):481-91
pubmed: 10924725
Am J Clin Nutr. 2014 Feb;99(2):384-91
pubmed: 24305679
Osteoarthritis Cartilage. 2010 May;18(5):601-4
pubmed: 20175975
Rheumatology (Oxford). 2018 Dec 1;57(12):2087-2095
pubmed: 29373736
Metabolites. 2019 Jan 09;9(1):
pubmed: 30634493
Diabetol Metab Syndr. 2014 Nov 27;6:129
pubmed: 25937838
Biochem Pharmacol. 2002 Jul 15;64(2):161-7
pubmed: 12123735
Mini Rev Med Chem. 2016;16(2):94-103
pubmed: 26471966
Nat Rev Rheumatol. 2014 Sep;10(9):515-6
pubmed: 25023454
Clin Biochem. 2005 Oct;38(10):925-33
pubmed: 16043165
Biochem Pharmacol. 2019 Jul;165:41-48
pubmed: 30831073
World J Gastroenterol. 2011 Mar 21;17(11):1468-74
pubmed: 21472106
BMC Bioinformatics. 2012 Jun 06;13:120
pubmed: 22672667
PLoS Genet. 2011 Aug;7(8):e1002215
pubmed: 21852955